The aim of this study is to learn how peoples’ bodies, particularly the skin, respond to tick bites.

The Vaccine Adjuvant Compendium (VAC) was launched in 2021 by the NIAID Division of Allergy, Immunology, and Transplantation (DAIT) to foster collaborations between NIAID-supported adjuvant researchers and the broader scientific community.

This 10- to 20-minute survey is available for patients with eczema or parents of patients with eczema.  These questions will help us learn more about patient experiences to improve current research and guide future research. 

What does the study involve?

This online survey involves 10 to 20 minutes’ worth of questions.

Who Can Participate?

Adults with eczema or parents/caregivers of a child with eczema.

Where Is It Taking Place?

This survey takes place online.

Is There a Cost?

No

Is Compensation Provided?

No

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population.

A pilot study has begun to assess the antibody response to a third dose of an authorized COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.

On World Asthma Day, the National Institutes of Health reaffirms its commitment to research to improve the lives of people with asthma. More than 25 million people in the United States have asthma, including 5.1 million children, according to the Centers for Disease Control and Prevention. This chronic lung disease can reduce quality of life, contributes to considerable emotional and financial stress, and is a major contributing factor to missed time from school and work.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE). This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop treatment and prevention approaches tailored to children of low-income families living in urban communities. NIAID intends to provide approximately $70 million over seven years to support the CAUSE network.

NIAID is recruiting NIH staff members to help researchers make discoveries about COVID-19 and influenza including learning about long-term immunity in people who receive COVID-19 and/or flu vaccines.